New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD exacerbation with a dry powder inhaler vs. a metered-dose or soft mist ...

Please provide your email address to receive an email when new articles are posted on . Invited patients had 32% of days covered for maintenance inhalers, whereas control patients had a smaller ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Leah J. Witt, MD: Hello. I'm Dr Leah Witt. Welcome to season one of Medscape InDiscussion, chronic obstructive pulmonary disease (COPD) podcast series. Today we're talking medications, especially ...

Researchers explained that educational level, duration of disease, and inhaler type may affect adherence in patients with chronic obstructive pulmonary disease (COPD). Most patients with chronic ...

Metered-dose inhaler propellants have contributed a rising amount to greenhouse gases in the U.S. Emissions per inhaler declined slightly over the past decade, but an increase in annual prescription ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Dry Powder Inhalers: A Double Win for COPD and Environment By Dennis Thompson HealthDay ReporterTUESDAY, Feb. 24, 2026 (HealthDay News) — Dry powder inhalers might provide a double benefit for people ...

Various types of inhalers, including short- and long-lasting options, are available for managing chronic obstructive pulmonary disease (COPD). A person can get a COPD inhaler through Medicare Part D ...

Add Yahoo as a preferred source to see more of our stories on Google. Inhalers that provide fast-acting treatment for people with certain respiratory conditions are contributing to greenhouse gas ...

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

The global pulmonary drug delivery technology market is projected to grow at a CAGR of approximately 5% over the next five years. This growth is driven by the rising prevalence of respiratory diseases ...